[{"id":"b68f78e2-ff40-4f10-a305-a75f5ad8aae1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00095901","created_at":"2021-12-29T15:53:29.497Z","updated_at":"2024-07-02T16:37:12.737Z","phase":"Phase 2","brief_title":"Capecitabine For Nasopharyngeal Cancer","source_id_and_acronym":"NCT00095901","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TYMP","pipe":"","alterations":" ","tags":["TYMP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 06/01/2004","start_date":" 06/01/2004","primary_txt":" Primary completion: 05/01/2007","primary_completion_date":" 05/01/2007","study_txt":" Completion: 05/01/2007","study_completion_date":" 05/01/2007","last_update_posted":"2018-03-29"}]